Biological Therapy, Therapeutic Approaches and Future Perspectives in the Treatment of Chronic Rhinitis
DOI:
https://doi.org/10.12775/QS.2024.18.52161Keywords
chronic rhinitis with nasal polyps, immunotherapy, monoclonal antibodies, allergic rhinitis, Quality of Life, omalizumabAbstract
Introduction: The widespread prevalence of chronic rhinitis necessitates the search for effective treatment methods. Modern type of medicine is biological treatment. Pathomechanism of AR is based on lymphocytes Th-2 reaction and connected with that cascade of effects. Biological treatment in the form of monoclonal antibodies blocks interleukins or immunoglobulin E signaling and leads to decrease in inflammatory reaction. Mechanism of action of these drugs and short period of use in AR requires patients to meet the including criteria and is usually used after other treatment options have run out. Taking under consideration the amount of patients suffering from AR and the impact on the quality of life indicates that there is still a need for new drugs and using drugs which are useful in similar diseases.
Purpose of the work: This study aims to review and evaluate biological drugs used or having the potential to be used in the treatment of allergic rhinitis (AR), including: omalizumab, dupilumab, mepolizumab, reslizumab and the possibility of their use on a wider scale in the future.
Materials and methods: An analysis of research papers available on PubMed and Google Scholar was undertaken using the following keywords: chronic rhinitis with nasal polyps; immunotherapy; monoclonal antibodies; allergic rhinitis; Quality of Life in rhinitis; omalizumab; dupilumab; mepolizumab; reslizumab; biological treatment during pregnancy;
Results: The use of biological drugs in AR results in a significant improvement in symptom control and an increase in quality of life. This option can be an effective form of treatment for nasal polyps, reducing the risk of needing sinus surgery. However, the criteria for using these drugs are still very limiting, due to the lack of specific biomarkers that could early indicate a high chance of success. Biological drugs seem to be a great opportunity and a worthwhile possibility in the treatment of people with chronic allergic rhinitis.
References
Liva GA, Karatzanis AD, Prokopakis EP. Review of Rhinitis: Classification, Types, Pathophysiology. J Clin Med. 2021;10(14). https://doi.org/10.3390/jcm10143183
Mullol J, del Cuvillo A, Lockey RF. Rhinitis Phenotypes. J Allergy Clin Immunol Pract. 2020;8(5):1492-1503. https://doi.org/10.1016/j.jaip.2020.02.004
Agnihotri NT, McGrath KG. Allergic and nonallergic rhinitis. Allergy Asthma Proc. 2019;40(6):376-379. https://doi.org/10.2500/aap.2019.40.4251
MS D, DV W, DJ A, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. https://doi.org/10.1016/j.jaci.2020.07.007
In-Depth Review of Allergic Rhinitis | World Allergy Organization. https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/in-depth-review-of-allergic-rhinitis (accessed 25 September 2023).
Rhinitis - European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). https://www.efanet.org/inform/patient-evidence/rhinitis (accessed 25 September 2023).
Maio S, Baldacci S, Carrozzi L, et al. Respiratory symptoms/diseases prevalence is still increasing: a 25-yr population study. Respir Med. 2016;110:58-65. https://doi.org/10.1016/J.RMED.2015.11.006
Janson C, Johannessen A, Franklin K, et al. Change in the prevalence asthma, rhinitis and respiratory symptom over a 20 year period: associations to year of birth, life style and sleep related symptoms. BMC Pulm Med. 2018;18(1). https://doi.org/10.1186/S12890-018-0690-9
Park S, Jung PK, Choi M, et al. Association between occupational clusters and allergic rhinitis in the Korean population: analysis of the Korean National Health and Nutrition Examination Survey data. J Occup Health. 2018;60(4):312-319. https://doi.org/10.1539/JOH.2017-0234-OA
Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. Int Forum Allergy Rhinol. 2023;13(4):293-859. https://doi.org/10.1002/ALR.23090
Czerwaty ABDEF K, Dżaman ABDEFG K, Miechowski CDF W, Godlewska IE. Leczenie biologiczne przewlekłego zapalenia zatok – aktualny stan wiedzy. Polski Przegląd Otorynolaryngologiczny. 2022;11(2):22-28. https://doi.org/10.5604/01.3001.0015.8538
Wojciech Brzoznowski. Standardy diagnostyczne i terapeutyczne alergicznego nieżytu nosa. Forum Medycyny Rodzinnej. 2009;3(3):173-180.
GWAS Catalog. https://www.ebi.ac.uk/gwas/ (accessed 27 September 2023).
Abramson MJ, Schindler C, Schikowski T, et al. Rhinitis in Swiss adults is associated with asthma and early life factors, but not second hand tobacco smoke or obesity. Allergol Int. 2016;65(2):192-198. https://doi.org/10.1016/J.ALIT.2015.11.004
Marenholz I, Esparza-Gordillo J, Rüschendorf F, et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march. Nat Commun. 2015;6. https://doi.org/10.1038/NCOMMS9804
Ojwang V, Nwaru BI, Takkinen HM, et al. Early exposure to cats, dogs and farm animals and the risk of childhood asthma and allergy. Pediatr Allergy Immunol. 2020;31(3):265-272. https://doi.org/10.1111/PAI.13186
Scadding GK, Smith PK, Blaiss M, et al. Allergic Rhinitis in Childhood and the New EUFOREA Algorithm. Frontiers in allergy. 2021;2. https://doi.org/10.3389/FALGY.2021.706589
Toelle BG, Ng KKW, Crisqfulli D, et al. Eight-year outcomes of the Childhood Asthma Prevention Study. J Allergy Clin Immunol. 2010;126(2):388-389.e3. https://doi.org/10.1016/J.JACI.2010.04.031
Behbod B, Sordillo JE, Hoffman EB, et al. Asthma and allergy development: contrasting influences of yeasts and other fungal exposures. Clin Exp Allergy. 2015;45(1):154-163. https://doi.org/10.1111/CEA.12401
Zou QY, Shen Y, Ke X, Hong SL, Kang HY. Exposure to air pollution and risk of prevalence of childhood allergic rhinitis: A meta-analysis. Int J Pediatr Otorhinolaryngol. 2018;112:82-90. https://doi.org/10.1016/J.IJPORL.2018.06.039
Li S, Wu W, Wang G, et al. Association between exposure to air pollution and risk of allergic rhinitis: A systematic review and meta-analysis. Environ Res. 2022;205. https://doi.org/10.1016/J.ENVRES.2021.112472
Lee KS, Rha YH, Oh IH, Choi YS, Choi SH. Socioeconomic and sociodemographic factors related to allergic diseases in Korean adolescents based on the Seventh Korea Youth Risk Behavior Web-based Survey: a cross-sectional study. BMC Pediatr. 2016;16(1). https://doi.org/10.1186/S12887-016-0549-2
Wee JH, Park MW, Min C, Park IS, Park B, Choi HG. The association between high hygiene scores and allergic rhinitis in Korean adolescents. Int Forum Allergy Rhinol. 2020;10(8):1024-1030. https://doi.org/10.1002/ALR.22569
Ekelund L, Gloppen I, Øien T, Simpson MR. Duration of breastfeeding, age at introduction of complementary foods and allergy-related diseases: a prospective cohort study. Int Breastfeed J. 2021;16(1). https://doi.org/10.1186/S13006-020-00352-2
Huang C, Liu W, Cai J, et al. Breastfeeding and timing of first dietary introduction in relation to childhood asthma, allergies, and airway diseases: A cross-sectional study. J Asthma. 2017;54(5):488-497. https://doi.org/10.1080/02770903.2016.1231203
Hoang MP, Samuthpongtorn J, Seresirikachorn K, Snidvongs K. Prolonged breastfeeding and protective effects against the development of allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2022;60(2):82-91. https://doi.org/10.4193/RHIN21.274
Han DH, Shin JM, An S, et al. Long-term Breastfeeding in the Prevention of Allergic Rhinitis: Allergic Rhinitis Cohort Study for Kids (ARCO-Kids Study). Clin Exp Otorhinolaryngol. 2019;12(3):301-307. https://doi.org/10.21053/CEO.2018.01781
Roduit C, Frei R, Depner M, et al. Increased food diversity in the first year of life is inversely associated with allergic diseases. J Allergy Clin Immunol. 2014;133(4). https://doi.org/10.1016/J.JACI.2013.12.1044
Nwaru BI, Takkinen HM, Kaila M, et al. Food diversity in infancy and the risk of childhood asthma and allergies. J Allergy Clin Immunol. 2014;133(4):1084-1091. https://doi.org/10.1016/J.JACI.2013.12.1069
Markevych I, Standl M, Lehmann I, von Berg A, Heinrich J. Food diversity during the first year of life and allergic diseases until 15 years. Journal of Allergy and Clinical Immunology. 2017;140(6):1751-1754.e4. https://doi.org/10.1016/j.jaci.2017.08.011
Hoehle LP, Phillips KM, Bergmark RW, Caradonna DS, Gray ST, Sedaghat AR. Symptoms of chronic rhinosinusitis differentially impact general health-related quality of life. Rhinology. 2016;54(4):316-322. https://doi.org/10.4193/RHINO16.211
Varendh M, Johannisson A, Hrubos-Strom H, Andersson M. Sleep quality improves with endoscopic sinus surgery in patients with chronic rhinosinusitis and nasal polyposis. Rhinology. 2017;55(1):45-52. https://doi.org/10.4193/RHIN16.065
Migueis DP, Lacerda GCB, Lopes MC, et al. Obstructive sleep apnea in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study. Sleep Med. 2019;64:43-47. https://doi.org/10.1016/J.SLEEP.2019.06.006
Chung JH, Lee YJ, Kang TW, et al. Altered Quality of Life and Psychological Health (SCL-90-R) in Patients With Chronic Rhinosinusitis With Nasal Polyps. Ann Otol Rhinol Laryngol. 2015;124(8):663-670. https://doi.org/10.1177/0003489415576181
Gray ST, Hoehle LP, Phillips KM, Caradonna DS, Sedaghat AR. Patient-reported control of chronic rhinosinusitis symptoms is positively associated with general health-related quality of life. Clin Otolaryngol. 2017;42(6):1161-1166. https://doi.org/10.1111/COA.12841
Speth MM, Hoehle LP, Phillips KM, Caradonna DS, Gray ST, Sedaghat AR. Changes in chronic rhinosinusitis symptoms differentially associate with improvement in general health-related quality of life. Ann Allergy Asthma Immunol. 2018;121(2):195-199. https://doi.org/10.1016/J.ANAI.2018.05.029
Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5. https://doi.org/10.1111/CEA.13491
Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: A Review of Present Indications and Off-Label Uses. J Investig Allergol Clin Immunol. 2022;32(2):97-115. https://doi.org/10.18176/JIACI.0682
Mullol J, Bachert C, Amin N, et al. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1086-1095.e5. https://doi.org/10.1016/j.jaip.2021.09.037
Fujieda S, Matsune S, Takeno S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status. Allergy. 2022;77(1):186. https://doi.org/10.1111/ALL.14906
Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. https://doi.org/10.4193/RHIN20.600
Hopkins C, Han JK, Lund VJ, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology. 2023;61(2):108-117. https://doi.org/10.4193/RHIN22.200
Fokkens W, Trigg A, Lee SE, et al. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study. J Patient Rep Outcomes. 2023;7(1):1-16. https://doi.org/10.1186/S41687-023-00543-5/FIGURES/8
Hopkins C, Han JK, Lund VJ, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology. 2023;61(2):108-117. https://doi.org/10.4193/RHIN22.200
Reslizumab - Medycyna Praktyczna. https://www.mp.pl/pacjent/leki/subst.html?id=5837 (accessed 26 September 2023).
Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-1141. https://doi.org/10.1016/J.JACI.2006.05.031
Mitchell PD, El-Gammal AI, O’Byrne PM. Anti-IgE and Biologic Approaches for the Treatment of Asthma. Handb Exp Pharmacol. 2017;237:131-152. https://doi.org/10.1007/164_2016_65
Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. Journal of Allergy and Clinical Immunology. 2005;115(3):459-465. https://doi.org/10.1016/j.jaci.2004.11.053
Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcεRI expression. Journal of Allergy and Clinical Immunology. 2003;112(6):1147-1154. https://doi.org/10.1016/j.jaci.2003.10.003
Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. Journal of Allergy and Clinical Immunology. 2004;113(2):297-302. https://doi.org/10.1016/j.jaci.2003.11.044
Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2(10):773-786. https://doi.org/10.1038/nri914
Pinto JM, Mehta N, DeTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318-324. https://doi.org/10.4193/RHINO09.144
Aldinger JP, Dobyns T, Lam K, Han JK. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021;21(9):1143-1149. https://doi.org/10.1080/14712598.2021.1962282
Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2(5):525-536.e1. https://doi.org/10.1016/J.JAIP.2014.03.010
CHMP. ANEKS I CHARAKTERYSTYKA PRODUKTU LECZNICZEGO - Xolair 75 Mg Proszek i Rozpuszczalnik Do Sporządzania Roztworu Do Wstrzykiwań.
Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol. 2020;59(1):38. https://doi.org/10.1007/S12016-020-08794-6
Nowicki RJ, Grubska-Suchanek E, Jahnz-Różyk K, et al. Urticaria. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society and the Polish Society of Allergology. Alergologia Polska - Polish Journal of Allergology. 2020;7(1):31-39. https://doi.org/10.5114/PJA.2020.93829
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1). https://doi.org/10.1016/J.JACI.2012.07.047
Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605. https://doi.org/10.1016/J.JACI.2020.05.032
Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60(6):435-443. https://doi.org/10.4193/RHIN22.129
Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51(6):836-844. https://doi.org/10.1111/CEA.13852
Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309-1317.e12. https://doi.org/10.1016/J.JACI.2021.08.030
Takabayashi T, Asaka D, Okamoto Y, et al. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy. 2021;35(6):861-870. https://doi.org/10.1177/19458924211009429
Kohli P, Naik AN, Harruff EE, Nguyen SA, Schlosser RJ, Soler ZM. The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope. 2017 Feb;127(2):309-320. https://doi.org/10.1002/lary.26316
Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I. Olfactory Dysfunction in the COVID-19 Outbreak. J Investig Allergol Clin Immunol. 2020;30(5):317-326. https://doi.org/10.18176/jiaci.0567
Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1487-1493. doi: 10.1007/s00405-016-4366-x
Akhlaghi A, Darabi A, Mahmoodi M, Movahed A, Kaboodkhani R, Mohammadi Z, Goreh A, Farrokhi S. The Frequency and Clinical Assessment of COVID-19 in Patients With Chronic Rhinosinusitis. Ear Nose Throat J. 2021 Aug 20:1455613211038070. https://doi.org/10.1177/01455613211038070
Reda A, Lashin BI, Alaaraj MM, Abouelkheir M, Ahmed MI, Shah J, El-Qushayri AE. The impact of chronic rhinosinusitis on COVID-19 risk and outcomes: A systematic review and meta-analysis. Front Immunol. 2023 Mar 29;14:1139031. https://doi.org/10.3389/fimmu.2023.1139031
Alroqi A, Abaalkhail MB, Albuhayjan N, Alorainy J, Jomah M, Alromaih S, Binkhamis K. Evaluation of Chronic Rhinosinusitis Symptoms' Severity Following COVID-19 Infection: A Retrospective Analysis. Cureus. 2023 May 3;15(5):e38517. https://doi.org/10.7759/cureus.38517
Workman AD, Bhattacharyya N. Do Patients With Chronic Rhinosinusitis Exhibit Elevated Rates of Covid-19 Infection? Laryngoscope. 2022 Feb;132(2):257-258. https://doi.org/10.1002/lary.29961
Wang H, Song J, Pan L, Yao Y, Deng YK, Wang ZC, Liao B, Ma J, He C, Zeng M, Liu Z. The characterization of chronic rhinosinusitis in hospitalized patients with COVID-19. J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3597-3599.e2. https://doi.org/10.1016/j.jaip.2020.09.013
Wang H, Song J, Yao Y, Deng YK, Wang ZC, Liao B, Ma J, He C, Pan L, Liu Y, Xie JG, Zeng M, Liu Z. Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis. Allergy. 2021 Mar;76(3):906-910. https://doi.org/10.1111/all.14569
Klimek L, Jutel M, Bousquet J, Agache I, Akdis CA, Hox V, Gevaert P, Tomazic PV, Rondon C, Cingi C, Toppila-Salmi S, Karavelia A, Bozkurt B, Förster-Ruhrmann U, Becker S, Chaker AM, Wollenberg B, Mösges R, Huppertz T, Hagemann J, Bachert C, Fokkens W. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Allergy. 2021 Mar;76(3):677-688. https://doi.org/10.1111/all.14629
Xu X, Reitsma S, Wang Y, Fokkens WJ. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021 Nov;76(11):3349-3358. https://doi.org/10.1111/all.14892
Genentech , Novartis : Omalizumab (Xolair) [package insert]. U.S. Food and Drug Administration website . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf (accessed 14 January 2024).
GSK. Mepolizumab (Nucala) [package insert]. U.S. Food and Drug Administration website. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF (accessed 14 January 2024).
TEVA. Reslizumab (Cinqair) [package insert]. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf (accessed 14 January 2024).
AstraZeneca. Benralizumab (Fasenra) [package insert]. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf (accessed 14 January 2024).
Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, Wang Y, Veith J, Andrews EB. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015 Feb;135(2):407-12. https://doi.org/10.1016/j.jaci.2014.08.025
Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM, Umetsu DT, Veith JH, Sun D, Kaufman DG, Covington DL, Mukhopadhyay S, Fogel RB, Lopez-Leon S, Spain CV. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020 Feb;145(2):528-536.e1. https://doi.org/10.1016/j.jaci.2019.05.019
Sanofi and Regeneron Pharmaceuticals. Dupilumab (Dupixent) [package insert]. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf (accessed 14 January 2024).
Ozden G, Pınar Deniz P. May mepolizumab used in asthma correct subfertility? Ann Med. 2021 Dec;53(1):456-458. https://doi.org/10.1080/07853890.2021.1900591
Manetz S, Maric I, Brown T, Kuang FL, Wetzler L, Battisto E, Klion AD. Successful pregnancy in the setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1405-1407.e3. https://doi.org/10.1016/j.jaip.2020.11.060
Gracia-Darder I, Pons De Ves J, Reyero Cortina M, Martín-Santiago A. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. Dermatol Ther. 2022 Feb;35(2):e15237. https://doi.org/10.1111/dth.15237
Lobo Y, Lee RC, Spelman L. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature. Case Rep Dermatol. 2021 May 4;13(2):248-256. https://doi.org/10.1159/000515246
Rom, D., Bassiouni, A., Eykman, E., Liu, Z., Paramasivan, S., Alvarado, R., … Harvey, R. J. (2019). The Association Between Disease Severity and Microbiome in Chronic Rhinosinusitis. The Laryngoscope. https://doi.org/10.1002/lary.27726
Endam LM, Alromaih S, Gonzalez E, Madrenas J, Cousineau B, Renteria AE, Desrosiers M. Intranasal Application of Lactococcus lactis W136 Is Safe in Chronic Rhinosinusitis Patients With Previous Sinus Surgery. Front Cell Infect Microbiol. 2020 Oct 12;10:440. https://doi.org/10.3389/fcimb.2020.00440
Fong P, Lim K, Gnanam A, Charn T. Role of probiotics in chronic rhinosinusitis: a systematic review of randomised, controlled trials. The Journal of Laryngology & Otology. 2023;137(12):1300-1311. https://doi.org/10.1017/S0022215123000543
Iftikhar, H., Awan, M. O., Awan, M. S., Mustafa, K., Das, J. K., & Ahmed, S. K.. (2022). Role of Probiotics in Patients with Allergic Rhinitis: A Systematic Review of Systematic Reviews. International Archives of Otorhinolaryngology, 26(4), 744–752. https://doi.org/10.1055/s-0042-1749370
Peng, Y., Li, A., Yu, L., & Qin, G. (2015). The Role of Probiotics in Prevention and Treatment for Patients with Allergic Rhinitis: A Systematic Review. American Journal of Rhinology & Allergy, 29(4), 292–298. https://doi.org/10.2500/ajra.2015.29.4192
Ahmad JG, Marino MJ, Luong AU. Unified Airway Disease: Future Directions. Otolaryngol Clin North Am. 2023;56(1):181-195. https://doi.org/10.1016/J.OTC.2022.09.014
Al-Ahmad M, Alsaleh S, Al-Reefy H, et al. Expert Opinion on Biological Treatment of Chronic Rhinosinusitis with Nasal Polyps in the Gulf Region. J Asthma Allergy. 2022;15:1. https://doi.org/10.2147/JAA.S321017
Liu T, Li TL, Zhao F, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci. 2011;341(1):40-47. https://doi.org/10.1097/MAJ.0B013E3181F20489
Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633-656. https://doi.org/10.1146/ANNUREV-PHARMTOX-010814-124407
Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521. https://doi.org/10.1146/ANNUREV.IMMUNOL.16.1.495
Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013;2013. https://doi.org/10.1155/2013/983902
Sands BE, Chen J, Feagan BG, et al. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study. Gastroenterology. 2017;153(1):77-86.e6. https://doi.org/10.1053/J.GASTRO.2017.03.049
Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004;4(8):1333-1344. https://doi.org/10.1517/14712598.4.8.1333
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis. 2009-04-20. https://www.clinicaltrialsgps.com/search-clinical-trials/trial-13750/ (accessed 14 January 2024).
Smith KA, Pulsipher A, Gabrielsen DA, Alt JA. Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions. Am J Rhinol Allergy. 2018;32(5):412-423. https://doi.org/10.1177/1945892418787132
Baruah B, Gupta A, Kumar A, Kumar A. The role of oral vitamin D3 supplementation in the treatment of Chronic Rhinosinusitis in adults with Vitamin D deficiency. J Family Med Prim Care. 2020;9(6):2877. https://doi.org/10.4103/JFMPC.JFMPC_448_20
Mulligan JK, White DR, Wang EW, et al. Vitamin D3 Deficiency Increases Sinus Mucosa Dendritic Cells in Pediatric Chronic Rhinosinusitis with Nasal Polyps. http://dx.doi.org/101177/0194599812448852. 2012;147(4):773-781. https://doi.org/10.1177/0194599812448852
Kirsche H, Niederführ A, Deutschle T, Fuchs C, Riechelmann H. Ratio of myeloid and plasmacytoid dendritic cells and TH2 skew in CRS with nasal polyps. Allergy. 2010;65(1):24-31. https://doi.org/10.1111/J.1398-9995.2009.02174.X
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agata Magierska, Zuzanna Szczepaniak, Olga Ptak, Krzysztof Gomułka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 118
Number of citations: 0
